Phaseline

Targets › DDC

DDC (Aromatic-L-amino-acid decarboxylase): drug programs, companies and trials

3 programs from 3 companies in 5 trials: 3 Phase 4, 1 Phase 2, 1 Phase 1; Metabolic and endocrine, Neurology, Psychiatry; next expected readout Aug 2027.

Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine and L-5-hydroxytryptophan to serotonin. (UniProt, P20711)

Open in Phaseline: the race on DDC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Impax LaboratoriesCarbidopa
DOPA decarboxylase inhibitor
DDCPhase 4Parkinson Disease; Anhedonia–
PTC TherapeuticsEladocagene Exuparvovec
DDC exogenous gene
DDCPhase 2AADC DeficiencyApr 2028
Krzysztof BankiewiczAAV2-hAADC
Adeno-associated virus serotype 2 expressing human aromatic L-amino acid decarboxylase
DDCPhase 1AADC DeficiencyAug 2027

Conditions

AADC Deficiency (2) Parkinson Disease (2) Anhedonia (1)

Modalities

other (2), small molecule (1)

Companies

PTC Therapeutics (1) Impax Laboratories (1) Krzysztof Bankiewicz (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.